MTX216

MTX216 is an investigational **small-molecule multi-kinase inhibitor** reported as a nominal PI3K and EGFR inhibitor that also inhibits SYK, with the available preclinical evidence indicating that its antitumor activity in **NF1 loss-of-function melanoma** depends importantly on SYK suppression. In AACR-published preclinical work, MTX216 showed strong in vitro and in vivo activity in NF1-altered melanoma models, reducing proliferation and ribosomal S6 phosphorylation, inducing apoptosis, and suppressing mitochondrial electron transport chain gene programs associated with poor prognosis in NF1-deficient melanoma. Publicly available information indicates it has been associated with development activities by MTX and evaluated primarily in the preclinical setting rather than as an approved medicine or established clinical-stage oncology product.